Table 1 Characteristics of excluded studies
| Â | Reasons for exclusion |
|---|---|
Lee 2012 [72] | Nonrandomized (cost-effectiveness analysis) |
Shiroiwa 2010 [73] | Nonrandomized (cost-effectiveness analysis) |
Zhang 2012 [74] | Nonrandomized |
Adjuvant treatment | |
Ducreux 2009 [77] | Different comparison (bevacizumab in both arms) |
Pectasides 2012 [78] | Different comparison (bevacizumab in both arms) |
Souglakos 2012 [79] | Different comparison (bevacizumab in both arms) |
DÃaz-Rubio 2012 [80] | Different comparison (bevacizumab in both arms) |
Price 2012 [81] | Subgroup analysis of another study |
Moehler 2009 [82] | Nonrandomized |